Skip to main content

Advertisement

Table 2 Diagnosis and extent of cancer in the Safety population (N = 32) at study entry

From: Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy

  No. of patients % of Safety population
Clinical tumor categories   
T2* 23 71.9
T3 5 15.6
T4a 1 3.1
T4b 3 9.4
Primary tumor histology   
Ductal 19 59.4
Invasive lobular/variant 8/1 25.0/3.1
Other/missing 3/1 9.4/3.1
Tumor grade   
Well/moderately/poorly differentiated 3/16/2 9.4/50.0/6.3
Missing 11 34.4
Positive receptor status   
Estrogen/progesterone/either 31/25/32 96.9/78.1/100.0
  1. * only if ineligible for breast-conserving surgery